Impact of Anti-cytomegalovirus (Valganciclovir) Treatment in the Management of Relapsing Ulcerative Colitis (UC) Requiring Vedolizumab Therapy

Condition:   Ulcerative Colitis, Unspecified Intervention:   Drug: Valganciclovir Sponsors:   Centre Hospitalier Universitaire de Saint Etienne;   Ministry of Health, France Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials